UM  > Institute of Chinese Medical Sciences
Residential Collegefalse
Status已發表Published
Canthin-6-One Accelerates Alpha-Synuclein Degradation by Enhancing UPS Activity: Drug Target Identification by CRISPR-Cas9 Whole Genome-Wide Screening Technology
Ning-Ning Yuan1; Cui-Zan Cai1; Ming-Yue Wu1; Qi Zhu1; HuanXing Su1; Min Li2; JiaoYan Ren3; Jie-Qiong Tan4; Jia-Hong Lu1
2019-01
Source PublicationFRONTIERS IN PHARMACOLOGY
ISSN1663-9812
Volume10
Other Abstract

Parkinson’s disease (PD) is the second most common neurodegenerative disorder characterized by the accumulation of protein aggregates (namely Lewy bodies) in dopaminergic neurons in the substantia nigra region of the brain. Alpha-synuclein (α-syn) is the major component of Lewy bodies in PD patients, and impairment of the ubiquitin-proteasome system has been linked to its accumulation. In this work, we developed a tetracycline–inducible expression system, with simultaneous induced expression of α-syn-EGFP and a bright red fluorescent protein marker (mCherry) to screen for potential compounds for degrading α-syn. We identified canthin-6-one as an α-syn lowering compound which promoted both wild type and mutants α-syn degradation in an ubiquitin-proteasome-system (UPS) dependent manner. By CRISPR/Cas9 genome-wide screening technology, we identified RPN2/PSMD1, the 26S proteasome non-ATPase regulatory subunit 1, as the targeting gene for pharmacological activity of canthin-6-one. Finally, we showed that canthin-6-one up-regulates PSMD1 and enhances UPS function by activating PKA.

KeywordCanthin-6-one Parkinson’s Disease Alpha-synuclein Ubiquitin-proteasome-system Crispr/cas9 Rpn2/psmd1 Pka
DOI10.3389/fphar.2019.00016
Indexed BySCIE
Language英語English
WOS Research AreaPharmacology & Pharmacy
WOS SubjectPharmacology & Pharmacy
WOS IDWOS:000456925900001
Scopus ID2-s2.0-85065338314
Fulltext Access
Citation statistics
Document TypeJournal article
CollectionInstitute of Chinese Medical Sciences
Corresponding AuthorJie-Qiong Tan; Jia-Hong Lu
Affiliation1.State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau,Macao, China
2.Mr. and Mrs. Ko Chi Ming Centre for Parkinson’s Disease Research, School of Chinese Medicine,Hong Kong Baptist University, Hong Kong, China
3.School of Food Science and Engineering, South China Universityof Technology, Guangzhou, China
4.Center for Medical Genetics, School of Life Sciences, Central South University,Changsha, China
First Author AffilicationInstitute of Chinese Medical Sciences
Corresponding Author AffilicationInstitute of Chinese Medical Sciences
Recommended Citation
GB/T 7714
Ning-Ning Yuan,Cui-Zan Cai,Ming-Yue Wu,et al. Canthin-6-One Accelerates Alpha-Synuclein Degradation by Enhancing UPS Activity: Drug Target Identification by CRISPR-Cas9 Whole Genome-Wide Screening Technology[J]. FRONTIERS IN PHARMACOLOGY, 2019, 10.
APA Ning-Ning Yuan., Cui-Zan Cai., Ming-Yue Wu., Qi Zhu., HuanXing Su., Min Li., JiaoYan Ren., Jie-Qiong Tan., & Jia-Hong Lu (2019). Canthin-6-One Accelerates Alpha-Synuclein Degradation by Enhancing UPS Activity: Drug Target Identification by CRISPR-Cas9 Whole Genome-Wide Screening Technology. FRONTIERS IN PHARMACOLOGY, 10.
MLA Ning-Ning Yuan,et al."Canthin-6-One Accelerates Alpha-Synuclein Degradation by Enhancing UPS Activity: Drug Target Identification by CRISPR-Cas9 Whole Genome-Wide Screening Technology".FRONTIERS IN PHARMACOLOGY 10(2019).
Files in This Item:
There are no files associated with this item.
Related Services
Recommend this item
Bookmark
Usage statistics
Export to Endnote
Google Scholar
Similar articles in Google Scholar
[Ning-Ning Yuan]'s Articles
[Cui-Zan Cai]'s Articles
[Ming-Yue Wu]'s Articles
Baidu academic
Similar articles in Baidu academic
[Ning-Ning Yuan]'s Articles
[Cui-Zan Cai]'s Articles
[Ming-Yue Wu]'s Articles
Bing Scholar
Similar articles in Bing Scholar
[Ning-Ning Yuan]'s Articles
[Cui-Zan Cai]'s Articles
[Ming-Yue Wu]'s Articles
Terms of Use
No data!
Social Bookmark/Share
All comments (0)
No comment.
 

Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.